Showing results (211-220 of 406) with videos related to

Sort By:
Pageof 41
Oncoimmunology|April 11, 2018
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapyAnnika Nelde, Daniel J Kowalewski, Linus Backert, et al.
Lancet (London, England)|July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 studyMeletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Frontiers in Immunology|November 17, 2022
CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapyLuca Julius Pape, Julia Hambach, Anna Josephine Gebhardt, et al.
The Lancet. Oncology|June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 studyPhilippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Hemasphere|March 2, 2023
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 TrialKatja Weisel, Meletios A Dimopoulos, Jesús San-Miguel, et al.
Arthritis Research & Therapy|October 17, 2019
Invariant natural killer T cells are functionally impaired in patients with systemic sclerosisAnn-Christin Pecher, Felix Kettemann, Elisa Asteriti, et al.
Oncotarget|October 27, 2015
Molecular and functional interactions between AKT and SOX2 in breast carcinomaThorsten Schaefer, Hui Wang, Perihan Mir, et al.
Molecular Cancer Therapeutics|March 12, 2009
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancerMarcus M Schittenhelm, Christian Kollmannsberger, Karin Oechsle, et al.
British Journal of Haematology|May 24, 2022
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR studyOla Landgren, Katja Weisel, Laura Rosinol, et al.
Frontiers in Immunology|July 30, 2019
Invariant NKT Cells From Donor Lymphocyte Infusions (DLI-iNKTs) Promote ex vivo Lysis of Leukemic Blasts in a CD1d-Dependent MannerSimona Jahnke, Hannes Schmid, Kathy-Ann Secker, et al.
Pageof 41